arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Alto Neuroscience, Inc.

ANRO Health Care Biotechnology: Pharmaceutical Preparations
$21.97
▼ -5.8% Today
as of Oct 23, 16:45 ET
Last 30 days -30.65% Sep 14 → Oct 23
$20.91 $23.80 $26.69 $29.59 $32.48 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$21.95
High
$22.45
Low
$21.45
Volume
$379,246
Avg Vol
$433,398
Mkt Cap
$993M
P/E (TTM)
—
Beta
—
52w High
$37.48
52w Low
$10.20
Div Yield
—
Shares Out
$35M

Recent Press Releases & News last 60 days · 6 items

Oct 19 · 13:33 MT Newswires
HC Wainwright Adjusts Alto Neuroscience Price Target to $60 From $55, Maintains Buy Rating
Oct 14 · 12:59 Zacks
Here's Why You Should Add ANRO Stock to Your Portfolio Now
Oct 2 · 07:48 MT Newswires
Alto Neuroscience Insider Sold Shares Worth $3,567,247, According to a Recent SEC Filing
▸ Show all 6 press releases & news Free account →

ANRO earnings at a glance

The options market is pricing a move of about ±23.1% after the report, a range of roughly $16.90 to $27.04 from today's $21.97. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±7.2% on average; after the most recent report on May 13, 2026 it moved -7.2%. That means options currently expect more movement than ANRO has typically delivered. ANRO beat the consensus EPS estimate in 2 of its last 4 reported quarters. Implied volatility is currently 196%. The share price of $21.97 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$10
$37
43% of range
Avg surprise (last 4)
-6.4%
Avg reaction (last 2)
-7.2%
0% positive
Latest IV / EM
196%
EM ±23.1% · $25 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.44$-1.96$-1.48$-1.00$-0.52 Actual $-1.97Actual $-2.33Actual $-2.44Actual $-0.76Actual $-0.60Actual $-0.62Actual $-0.53Est $-0.59Actual $-0.65Est $-0.57Actual $-0.52Est $-0.66Actual $-0.80Est $-0.56Actual $-0.65 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-28M$-24M$-21M$-18M$-15M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.65 — — — — financials
Wed May 13, 2026Mar/2026 $-0.80 $-0.56 -42.9% -50.9% -7.2% earnings
Wed Nov 12, 2025Sep/2025 $-0.52 $-0.66 +21.2% — — earnings
Wed Aug 13, 2025Jun/2025 $-0.65 $-0.57 -14.0% — — earnings
Wed May 14, 2025Mar/2025 $-0.53 $-0.59 +10.2% — -7.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.62 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.60 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.76 — — — — financials
Sat Sep 30, 2023Sep 2023 $-2.44 — — — — financials
Fri Jun 30, 2023Jun 2023 $-2.33 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.97 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-29M$-27M—$-15M$-19M$-16M—$-19M
Net income$-28M$-26M—$-14M$-18M$-15M—$-17M
EPS (diluted)$-0.65$-0.80—$-0.52$-0.65$-0.56—$-0.62

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$244M$264M$176M$138M$148M$161M$168M$182M
Inventory————————
Total current assets$247M$269M$178M$139M$150M$164M$169M$184M
Total assets$254M$276M$185M$147M$158M$172M$178M$192M
Long-term debt$12M$14M$16M$20M$20M$20M$10M$7M
Total liabilities$35M$33M$34M$35M$34M$33M$26M$27M
Total equity$219M$243M$151M$112M$123M$139M$151M$165M

Implied volatility — last 90 days

63%148%233%318%403% Jun 07 — IV 212% · EM ±29.3%Jun 08 — IV 208% · EM ±27.4%Jun 09 — IV 226% · EM ±28.4%Jun 10 — IV 247% · EM ±29.2%Jun 11 — IV 237% · EM ±26.1%Jun 15 — IV 327% · EM ±23.6%Jun 16 — IV 403% · EM ±23.8%Jun 19 — IV 86% · EM ±18.9%Jun 22 — IV 109% · EM ±22.7%Jun 23 — IV 138% · EM ±28.3%Jun 24 — IV 99% · EM ±19.8%Jun 25 — IV 111% · EM ±21.8%Jun 26 — IV 114% · EM ±21.8%Jun 29 — IV 114% · EM ±20.2%Jun 30 — IV 158% · EM ±27.3%Jul 01 — IV 131% · EM ±22.0%Jul 02 — IV 131% · EM ±21.2%Jul 03 — IV 136% · EM ±21.2%Jul 06 — IV 152% · EM ±21.1%Jul 07 — IV 175% · EM ±23.2%Jul 08 — IV 208% · EM ±26.1%Jul 09 — IV 124% · EM ±14.7%Jul 10 — IV 203% · EM ±22.5%Jul 13 — IV 267% · EM ±22.3%Jul 14 — IV 172% · EM ±12.4%Jul 15 — IV 362% · EM ±21.4%Jul 16 — IV 355% · EM ±14.8%Jul 20 — IV 124% · EM ±29.3%Jul 21 — IV 77% · EM ±17.9%Jul 22 — IV 71% · EM ±16.2%Jul 23 — IV 85% · EM ±19.2%Jul 24 — IV 84% · EM ±18.5%Jul 27 — IV 120% · EM ±25.0%Jul 28 — IV 86% · EM ±17.6%Jul 29 — IV 91% · EM ±18.2%Jul 30 — IV 109% · EM ±21.3%Jul 31 — IV 96% · EM ±18.3%Aug 03 — IV 92% · EM ±16.3%Aug 04 — IV 140% · EM ±24.1%Aug 05 — IV 126% · EM ±21.0%Aug 06 — IV 103% · EM ±16.7%Aug 07 — IV 93% · EM ±14.5%Aug 10 — IV 94% · EM ±13.0%Aug 11 — IV 109% · EM ±14.4%Aug 12 — IV 127% · EM ±15.9%Aug 13 — IV 162% · EM ±19.1%Aug 14 — IV 105% · EM ±11.6%Aug 17 — IV 192% · EM ±16.1%Aug 18 — IV 211% · EM ±15.2%Aug 20 — IV 189% · EM ±7.9%Aug 24 — IV 74% · EM ±15.4%Aug 25 — IV 85% · EM ±17.4%Aug 26 — IV 71% · EM ±14.2%Aug 27 — IV 70% · EM ±13.8%Aug 28 — IV 75% · EM ±14.4%Aug 31 — IV 63% · EM ±11.2%Sep 01 — IV 85% · EM ±14.6%Sep 02 — IV 77% · EM ±12.8%Sep 03 — IV 75% · EM ±12.2%Sep 04 — IV 77% · EM ±12.1%Sep 07 — IV 87% · EM ±12.1%Sep 08 — IV 84% · EM ±11.1%Sep 09 — IV 111% · EM ±13.9%Sep 10 — IV 108% · EM ±12.8%Sep 11 — IV 107% · EM ±11.9%Sep 14 — IV 204% · EM ±17.0%Sep 15 — IV 182% · EM ±13.1%Sep 16 — IV 299% · EM ±17.7%Sep 21 — IV 95% · EM ±19.9%Sep 22 — IV 76% · EM ±15.6%Sep 23 — IV 89% · EM ±17.9%Sep 24 — IV 131% · EM ±25.8%Sep 25 — IV 121% · EM ±23.2%Sep 28 — IV 131% · EM ±23.3%Sep 29 — IV 78% · EM ±13.4%Sep 30 — IV 134% · EM ±22.3%Oct 01 — IV 131% · EM ±21.1%Oct 02 — IV 132% · EM ±20.6%Oct 06 — IV 205% · EM ±27.0%Oct 07 — IV 188% · EM ±23.6%Oct 08 — IV 196% · EM ±23.1%

Sector peers

PCRX
Pacira BioSciences, Inc.
$1.0B $36.42+0.2%
KURA
Kura Oncology, Inc.
$949M $9.61-2.7%
OPK
Opko Health, Inc.
$1.0B $1.63+1.9%
MLTX
MoonLake Immunotherapeutics
$917M $11.85+11.3%
ABUS
Arbutus Biopharma Corporation
$902M $4.20+0.5%
JANX
Janux Therapeutics, Inc.
$1.1B $16.66-1.6%

ANRO earnings FAQ

What is ANRO's expected move for earnings?

Options currently price a move of about ±23.1%, or $5.07 per share either way from $21.97.

How does ANRO stock usually react to earnings?

Across the last 2 reports the average next-day move was ±7.2%, up 0 times and down 2 times.

What is ANRO's implied volatility?

ANRO's at-the-money implied volatility is about 196% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in